The inflammatory cytokines. New developments in the pathophysiology and treatment of septic shock

Drugs

Volumn 52, Issue SUPPL. 2, 1996, Pages 9-17

  Glauser, Michel P ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIBODY; ANTIINFECTIVE AGENT; BACTERIAL TOXIN; BACTERIUM LIPOPOLYSACCHARIDE; CD14 ANTIGEN; CORTICOSTEROID; CYTOKINE; HIGH DENSITY LIPOPROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; MONOCLONAL ANTIBODY; PENTOXIFYLLINE; PROTEIN ANTIBODY; SUPERANTIGEN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

BACTERIAL CELL WALL; BLOOD CLOTTING; CELL STIMULATION; CLINICAL TRIAL; COMPLEMENT SYSTEM; CONFERENCE PAPER; DRUG ACTIVITY; ENDOTHELIUM CELL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; MACROPHAGE; MONOCYTE; NONHUMAN; PATHOPHYSIOLOGY; SEPTIC SHOCK;

BACTERIA (MICROORGANISMS); NEGIBACTERIA; POSIBACTERIA;

EID: 0029846775     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199600522-00004     Document Type: Conference Paper

References (35)

1. Anon. Increase in national hospital discharge survey rates for septicemia - United States. 1979-1987. MMWR 1990; 39: 31-4
2. Bone RC. Gram-positive organisms and sepsis. Arch Intern Med 1994; 154: 26-34
3. Weidemann B, Brade H, Rietschel HT, et al. Soluble peptidoglycan-induced monokine production can be blocked by anti-CD 14 monoclonal antibodies and by lipid A partial structures. Infect Immun 1994; 62: 4709-15
4. Heumann D, Gallay P, Barras C, et al. Control of lipopolysaccharide (LPS) binding and LPS-induced tumor necrosis factor secretion in human peripheral blood monocytes. J Immunol 1992; 148: 3505-12
5. Wright SD, Ramos RA, Tobias PS, et al. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990; 249: 1431-3
6. Ulevitch RJ, Tobias PS. Recognition of endotoxin by cells leading to transmembrane signalling. Curr Opin Immunol 1994; 6: 25-30
7. Heumann D, Barras, C, Severin A, et al. Gram-positive cell walls stimulatc synthesis of tumour necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun 1994; 62: 2715-21
8. Ziegler EJ, Fisher CJ, Sprung CL, et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibodt against endotoxin: a randomised, doubie-blind, placebo-controlled trial. New Engl J Med 1991; 324: 429-36
9. Anon. Another sepsis drug down: Chiron's T-88 shows no patient survival benefit. Biotechnol Newsl 1994; May 16: 4
10. Greenman RL, Schein RMH, Martin MA, et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. JAMA 1991; 266: 1097-1102
11. Bone RC, Balk RA, Fein AM, et al. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit Care Med 1995; 23: 994-1005
12. Di Padova F, Brade H, Barclay GR, et al. A broadly cross-protective monoclonal antibody binding to Escherichia coli and Salmonella lipopolysaccharides. Infect Immun 1993; 61: 3863-72
13. Wilde CG, Seilhamer JJ, McGrogan M, et al. Bactericidal/permeability-increasing protein and lipopolysaccharide (LPS)-binding protein: LPS binding properties and effects on LPS-mediated cell activation. J Biol Chem 1994; 269: 17411-6
14. Levine DM, Parker TS, Donnelly TM, et al. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993; 90: 12040-4
15. Haziot A, Rong G-W, Bazil V, et al. Recombinant soluble CD14 inhibits LPS-induced tumor necrosis factor-α production by cells in whole blood. J Immunol 1994; 152: 5868-76
16. Haziot A, Rong GW, Lin XY, et al. Recombinant soluble CD14 prevents mortality in mice treated with endotoxin (lipopolysaccharide). J Immunol 1995; 154: 6529-32
17. Leturcq D, Moriarty AM, Talbott G, et al. Therapeutic strategies to block LPS interactions with its receptor. In: Levin J, Alving CR, Munford RS, et al. editors. Bacterial endotoxins: lipopolysaccharides from genes to therapy. New York:Wiley-Liss Inc, 1995: 473-7
18. Gallay P, Heumann D, Le Roy D, et al. Mode of action of antilipopolysaccharide-binding protein antibodies for prevention of endotoxemic shock in mice. Proc Natl Acad Sci USA 1994; 91: 7922-6
19. Gallay P, Heumann D, Le Roy D, et al. Lipopolysaccharide-binding protein as a major plasma protein responsible for endotoxemic shock. Proc Natl Acad Sci USA 1993; 90: 9935-8
20. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-4
21. Fisher CJ, Opal SM, Dhainaut JF, et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993; 21: 318-27
22. Reinhart K, Weigand-Löhnert C, Grimmer E et al. Safety and efficacy of the monoclonal anti-TNF fragment MAK 195F in patients with sepsis and septic shock [abstract]. Shock 1995; 3 (Suppl.): 63
23. Wherry J, Wenzel R, Wunderink R, et al. Monoclonal antibody to human necrosis factor (TNF MAb): multi-center efficacy and safety study in patients with the sepsis syndrome [abstract no. 696). Proceedings of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy: 1993 Oct 18: New Orleans: 1993
24. Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor α in patients with sepsis syndrome: a randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995; 273: 934-41
25. Carlet J, Cohen J, Andersson J, et al. An international efficacy and safety study of monoclonal antibody to human necrosis factor in patients with the sepsis syndrome [abstract no. B/1]. Proceedings of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4-7: Orlando: 1994
26. Mancilla J, Garcia P, Dinarello CA. The interleukin-receptor antagonist can either reduce or enhance the lethality of Klebsiella pneumoniae sepsis in newborn rats. Infect Immun 1993; 61: 926-32
27. Wakabayashi G, Gelfand JA, Burke JF, et al. A specific antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J 1991; 5: 338-43
28. Alexander HR, Doherty GM, Buresh CM, et al. A recombinant human receptor antagonist to interleukin 1 improves survival after lethal endotoxemia in mice. J Exp Med 1991; 173: 1029-32
29. Fisher Jr CJ, Slotman GJ, Opal SM, et al. Initial evaluation of human recombinant interleukin 1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled trial. Crit Care Med 1994; 22: 12-21
30. Fischer Jr CJ, Dhainaut J-FA, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double blind, placebo-controlled trial. JAMA 1994; 271: 1836-43
31. Anon. Synergen drops Antril or sepsis. Scrip 1994; 1942: 10
32. Dembic Z, Loetscher H, Gubler U, et al. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 1990; 2: 231-7
33. Loetscher H, Angehrn P, Schlaeger EJ, et al. Efficacy of a chimeric TNFR-IgG fusion protein to inhibit TNF activity in animal models of septic shock. In: Levin J, Alving CR, Munford RS, et al., editors. Bacterial endotoxin: recognition and effector mechanisms. Amsterdam: Elsevier Science Publishers BV, 1993; 455-62
34. Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548-61
35. Agosti JM, Fisher CJ, Opal SM, et al. Treatment of sepsis syndrome with soluble TNF receptor (sTNFR) [abstract no. M4]. Proceedings ot the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1994 Oct 4-7; Orlando: 1994: 65